Latest technology reporting
Evidence-led coverage of biotechnology, AI infrastructure, energy, robotics, devices and brain–computer interfaces.
-
An 82% Response Rate in Pancreatic Cancer Still Needs a Randomised Test
A small Phase I/II study has reported tumour responses in 82% of evaluable patients with a biomarker-defined form of advanced pancreatic cancer. The result is striking, but the non-randomised dataset cannot show how much benefit the combination adds.
-
Nvidia’s Next Bottleneck Is the Factory Network Behind the GPU
Nvidia has announced agreements intended to expand substrate, packaging, testing and optical-engine capacity through 2028. The plan exposes the many industrial steps behind AI accelerators—and most of the promised capacity is not online yet.
-
Meta Makes AMD Training Competitive by Rewriting the Software Around the Chip
A Meta–AMD preprint reports production recommendation-model training on tens of thousands of MI350X accelerators at roughly the throughput of Meta’s established Nvidia B200 baseline. The result depends on extensive model, kernel and systems co-design.
-
Les Sablons Pushes French Batteries Beyond the Two-Hour Pattern
Enertrag’s 39 MW/117 MWh Les Sablons battery has reached financial close and entered construction in northern France. Its three-hour duration is notable, but operation remains targeted for spring 2027.
-
A $967 Million Grid Announcement Starts an Allocation Process, Not Construction
The US Energy Department has opened access to about $967 million in grid-resilience formula funding. States and tribes must apply and then select eligible projects; the announcement is not evidence that $967 million of construction has begun.
-
OPGx-RDH12 Clears the Gate to Human Testing, Not the Finish Line
The FDA has cleared Opus Genetics to begin a Phase I/II study of OPGx-RDH12 for a rare inherited retinal disease. IND clearance authorizes a trial; no participant has yet supplied human safety or efficacy data.
-
BioNTech Rebuilds a Phase III Breast-Cancer Trial Around Trodelvy
BioNTech plans to compare pumitamig plus Trodelvy with Trodelvy alone in a redesigned Phase III trial for PD-L1-low or negative triple-negative breast cancer. The change raises the clinical bar; the combination remains unapproved.
-
ER-100 Reaches Humans, but Three Glaucoma Patients Cannot Prove Rejuvenation
Life Biosciences has reported the first three participants in a Phase I trial of ER-100. The safety update permits dose escalation, but the tiny open-label dataset cannot establish restored vision or human rejuvenation.
-
Nutanix and Supermicro Package Private AI Before Proving the Cost per Token
Nutanix and Supermicro plan a full-stack private-inference system for early 2027. The architecture is specified, but availability and cost-per-token claims still await measured deployments.
-
OpenAI’s Google Cloud Deal Changes the Buying Route, Not the Model Owner
OpenAI models are coming to Google Cloud’s Model Garden, beginning with a private preview. The integration changes procurement and governance options without making the models Google technology.
-
Peak Energy’s $108 Million Round Funds a Sodium-Ion Scale Test
Peak Energy has raised $108 million to expand sodium-ion storage and manufacturing. Financing, contracts and planned factory capacity are signals of demand—not proof of long-term cost or operating performance.
-
Huntly’s 200 MWh Battery Is Operating While Stage Two Remains on Paper
Genesis Energy has opened a 100 MW/200 MWh battery at Huntly. A second project has reached an investment decision, but it is a separate future asset rather than capacity already online.